{"id":"finaldose","n":"FinalDose","t":176,"s":{"what_it_does":"FinalDose develops programmable medicines designed to identify diseased cells through their DNA and destroy them while leaving healthy cells untouched. Its platform combines DNA recognition, guide-based targeting and cell elimination. By changing the guide sequence, FinalDose aims to adapt a therapeutic architecture to mutations and diseases. The focus is cancers driven by genetic mutations that conventional protein-based drugs cannot reach.","best_for":"Pharmaceutical companies, oncology researchers, biotechnology partners and investors exploring programmable medicines and DNA-targeted cancer therapies.","sets_apart":"FinalDose targets disease-causing DNA signatures directly, aiming to eliminate affected cells rather than inhibit proteins.","entity_type":"Programmable therapeutics company","products_services":"DNA-targeted therapeutics that detect disease-associated sequences and activate a cytotoxic response","technology":"FDCas platform, DNA recognition, guide-based programming and selective cell elimination","use_cases":"Genetically defined cancers","leadership":"Jeff Liu, Li-Yao Huang and Steven Lin, founders"},"url":"https://www.finaldose.ai","img":"https://milliontokenwindow.com/i/4cd28fff36161ca7fd75e3ecc1a2a61b00ce6a81888ef277edc132f17a09a0a2.webp","c":"health-life-sciences","loc":[37.7749,-122.4194],"hub":"San Francisco, United States","p":"2026-09-13"}